Omalizumab prevents respiratory illnesses in non‐atopic chronic spontaneous urticaria patients: A prospective, parallel‐group, pilot pragmatic trial

BACKGROUND: Omalizumab is the recommended treatment for antihistamine‐refractory chronic spontaneous urticaria (CSU) and severe allergic asthma. In addition, it has been shown to reduce the frequency of viral respiratory infections in allergic asthma. Respiratory illness is a known trigger for asthm...

Descripción completa

Detalles Bibliográficos
Autores principales: Konstantinou, George N., Podder, Indrashis, Karapiperis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339798/
https://www.ncbi.nlm.nih.gov/pubmed/37488725
http://dx.doi.org/10.1002/clt2.12279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339798/
https://www.ncbi.nlm.nih.gov/pubmed/37488725
http://dx.doi.org/10.1002/clt2.12279

Ejemplares similares